Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study

eLife(2022)10.7554/elife.77943Source: DataRank Database

Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study is a research paper published in eLife (2022). On theSindex it has a DataRank of 0.769. It has been cited 19 times, with 17 citing works in its 1-hop citation network.

N/A

0.769DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access19 citations · 17 citing works in its network

Download PDF

Cite:

Linked data & code

geo nct doi

Data availability

Repositories this paper deposited data in (declared in PubMed).

GEOGSE178967

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (17 grants)Impact (FWCI 2.00)OA: goldTopics (112)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 58%Citation Network 42%

Base Score Contribution

0.449

From this paper's citation signal

Citation Network Contribution

0.320

From 15 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 17 citers.

Cxcl10 is protective during mouse-adapted SARS-CoV-2 infection
Journal of Leukocyte Biology20245 citations33 referencesContributes 0.054
Cytokine immune profiles among COVID 19 patients with different disease severities seeking treatment at Moi teaching and referral hospital, Kenya
Cytokine20251 citations14 referencesContributes 0.050
Tracking Rare Single Donor and Recipient Immune and Leukemia Cells after Allogeneic Hematopoietic Cell Transplantation Using Mitochondrial DNA Mutations
Blood Cancer Discovery20249 citations53 referencesContributes 0.043
Coronavirus disease 2019–related myocardial injury is associated with immune dysregulation in symptomatic patients with cardiac magnetic resonance imaging abnormalities
Cardiovascular Research20249 citations63 referencesContributes 0.037
Longitudinal home self-collection of capillary blood using home RNA correlates interferon and innate viral defense pathways with SARS-CoV-2 viral clearance
medRxiv20233 citations43 referencesContributes 0.032

Authors (27)

Kattria van der Ploeg ORCID,Saborni Chakraborty ORCID,Prabhu S. Arunachalam ORCID,Diego AM Mori,Karen B. Jacobson ORCID

Live enrichment

PubMed:36239699 PMC:PMC9566856 OpenAlex:https://openalex.org/W4306174581

National Institute of Allergy and Infectious Diseases

Grant: U01 AI150741-01S1

Stanford University

Grant: Stanford's Innovative Medicines Accelerator

National Institute on Drug Abuse

Grant: DP1DA046089

National Institute of Allergy and Infectious Diseases

Grant: T32-AI052073

NIAID NIH HHS

Grant: U01 AI150741

NIAID NIH HHS

Grant: U19 AI167903

NIAID NIH HHS

Grant: K23 AI076614

NIAID NIH HHS

Grant: T32 AI007502

NIAID NIH HHS

Grant: K24 AI144048

Stanford University

Grant: Stanford's Innovative Medicines Accelerator

NIAID NIH HHS

Grant: T32 AI052073

NCATS NIH HHS

Grant: UL1 TR003142

NIAID NIH HHS

Grant: U19 AI057229

National Institutes of Health

Grant: 5T32AI052073-08

Epidemiology of Emerging Infectious Diseases and Bioterrorism

National Institutes of Health

Grant: 5UL1TR001085-05

Spectrum Stanford Center for clinical and Translational Research and Education

National Institutes of Health

Grant: 5DP1DA046089-02

Targeting natural killer cells to HIV in intravenous drug users

National Institutes of Health

Grant: 5U01AI150741-02

Computational models of naturally acquired immunity to falciparum malaria

FWCI

2.00

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.7554/elife.77943

publisherhttps://doi.org/10.7554/elife.77943

publisherhttps://cdn.elifesciences.org/articles/77943/elife-77943-v2.pdf

publisherhttps://cdn.elifesciences.org/articles/77943/elife-77943-v2.xml

publisherhttps://elifesciences.org/articles/77943

Fields of Study

Long-Term Effects of COVID-19SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies0301 basic medicine0303 health sciences03 medical and health sciencesHumansAntibodies, ViralBiomarkersBNT162 VaccineCOVID-19CytokinesDisease ProgressionRNA, MessengerSARS-CoV-2Clinical Trials as Topic

MeSH Terms

COVID-19SARS-CoV-2BNT162 VaccineAntibodies, ViralClinical Trials as TopicHumansRNA, MessengerBiomarkersCytokinesDisease Progression

Keywords

Immune systemImmunologyAntibodyViral sheddingMedicineDiseaseVaccinationVaccine trialClinical trialBiologyInternal medicineVirusesInflammationPredictive modelingSystems ImmunologyCovid-19Prevention (rcdc)CoronavirusesMessengerDisease Progression (mesh)BNT162 Vaccine (mesh)Antibodies, ViralClinical Research (rcdc)Immunology and InflammationPrecision Medicine (rcdc)31 Biological sciences (for-2020)Machine Learning and Artificial Intelligence2.1 Biological and endogenous factorsViralPrecision MedicineImmunization (rcdc)Biology (General)32 Biomedical and Clinical Sciences (for-2020)Humans (mesh)Clinical Trials as Topic3 Good Health and Well Being (sdg)COVID-19 (mesh)QRBiological sciencesInfection (hrcs-hc)Biomarkers (mesh)Infectious DiseasesVaccine Related (rcdc)Disease ProgressionCytokinesInfectionMachine Learning and Artificial Intelligence (rcdc)BiotechnologyQH301-705.5Science0601 Biochemistry and Cell Biology (for)610SARS-CoV-2 (mesh)Clinical Trials as Topic (mesh)Biotechnology (rcdc)Emerging Infectious Diseases (rcdc)AntibodiesVaccine Related618Clinical ResearchViral (mesh)42 Health sciences (for-2020)HumansRNA, Messenger3204 Immunology (for-2020)BNT162 VaccineMessenger (mesh)Biomedical and Clinical SciencesSARS-CoV-2PreventionInflammatory and immune system4.1 Discovery and preclinical testing of markers and technologies (hrcs-rac)Health sciencesCoronaviruses (rcdc)2.1 Biological and endogenous factors (hrcs-rac)4.1 Discovery and preclinical testing of markers and technologiesInflammatory and immune system (hrcs-hc)Emerging Infectious DiseasesGood Health and Well BeingCytokines (mesh)Infectious Diseases (rcdc)RNAImmunizationBiochemistry and Cell BiologyBiomarkers

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being